Navigation Links
Cepheid Reports 2013 First Quarter Results
Date:4/18/2013

7.421.428%Non-Clinical & Other

0.91.5-40%Total International28.322.924%Total Sales$
91.9$
77.319%


  • During the quarter, Cepheid installed a total of 125 GeneXpert systems in its commercial Clinical business.  Additionally, the Company placed a total of 157 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.  Including the HBDC systems, a cumulative total of 4,117 GeneXpert systems have been placed worldwide as of March 31, 2013.
  • GAAP gross margin on sales was 53% and non-GAAP gross margin on sales was 55%, which compares to 54% and 55%, respectively, in the first quarter of 2012. 
  • Cash and cash equivalents were $102.0 million as of March 31, 2013.
  • DSO was 45 days.
  • Business OutlookFor the fiscal year ending December 31, 2013, the Company continues to expect:

  • Total revenue to be in the range of $375 to $385 million;
  • Net income to range from a net loss of $(0.05) to net income of $0.01 per share; 
  • Non-GAAP net income in the range of $0.41 to $0.46 per share. 
  • Expected non-GAAP net income excludes approximately $29 million related to stock compensation expense and approximately $4 million related to the amortization of acquired intangibles.  The fully diluted share count for the year is expected to be approximately 72 million, except in the event of a GAAP loss where the share count would be approximately 67 million shares.

    The following table reconciles net income (loss) per share to the non-GAAP net income per share range:Guidance Range for YearEnding December 31, 2013Low HighNet Income (Loss) Per Share$
    (0.05)$
    .01Stock Compensation Expense0.400.39Amortization of Purchased Intangible Assets0.060.06Non-GAAP Measure of Net Income Per Share$
    .41$
    .46Accessing Cepheid's 2013 First Quarter Results Conference CallThe Company will host a management presentation at 2 p.m. Pacific Time on
    '/>"/>

    SOURCE Cepheid
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
    2. Cepheid Announces Board of Directors Changes
    3. Cepheid Reports 2012 Second Quarter Results
    4. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
    5. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
    6. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
    7. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
    8. Cepheid to Webcast Upcoming Financial Presentations
    9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
    10. Cepheid Welcomes Senior Vice President of Human Resources
    11. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... The Activated Carbon Manufacturing industry ... IBISWorld updated its original industry research report. , ... intensified focus on environmental policy. Over the five years ... power plants and a range of other industrial facilities ... Sarah Kahn, “a range of downstream industrial sectors rely ...
    (Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
    (Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
    (Date:12/17/2014)... Dec. 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary commercial focus on ... granted a Type C meeting with the U.S. Food ... be held in February 2015.  During this meeting the ...
    Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
    ... , A ... coded affinity tags is to correctly identify and obtain accurate ... by mass spectrometry. Because MALDI-TOF mass spectrometry can easily generate ... used to quickly screen the ICAT reagent pairs representing the ...
    ... G. Vjial, M. Lamor, V. Pop and ... Introduction , ... and misused in sport. They are very potent drugs in the ... on the nervous system and can improve an athletes ability to ...
    ... , D. Garteiz, R. Morrow, and ... Schmidt, Varian, Inc., Walnut Creek, CA , ... Flavonoids are compounds that make up the pigments ... multiple beneficial therapeutic effects for a large number of serious illnesses, such ...
    Cached Biology Technology:Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool 2Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool 3Screening of Corticosteroids in Urine by Negative Atmospheric Pressure Chemical Ionization LC/MS/MS 2Screening of Corticosteroids in Urine by Negative Atmospheric Pressure Chemical Ionization LC/MS/MS 3Screening of Corticosteroids in Urine by Negative Atmospheric Pressure Chemical Ionization LC/MS/MS 4Quantitation of a Dinitro Flavonoid (DNF) in Rat Plasma Using the Varian 1200L LC/MS/MS System 2Quantitation of a Dinitro Flavonoid (DNF) in Rat Plasma Using the Varian 1200L LC/MS/MS System 3
    (Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
    (Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
    (Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
    Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
    ... Biliopancreatic diversion surgery for morbid obesity is known to ... the June issue of the Journal of AAPOS , ... and Strabismus, a group of Australian clinicians report a child ... deficiency caused by his mother,s obesity surgery. Clinical ...
    ... of the first plants that colonized land and reproduced ... pests and habitat loss, especially those species endemic to ... published recently as the cover article in Molecular ... plants as relicts (leftovers of formerly abundant organisms), and ...
    ... if I were grown only so that my organs could be harvested, ... too, while I wait for my own death? What if doctors cut ... in a lab for the next sixty years? What if scientists discovered ... at me? In the spirit of summer, and especially summer reading, ...
    Cached Biology News:Vitamin deficiency after weight loss surgery can cause vision loss in newborns 2New research on rapidly disappearing ancient plant offers hope for species recovery 2New research on rapidly disappearing ancient plant offers hope for species recovery 3Bioethics beach reading, Summer 2010 edition 2
    ... 1;The Human Embryonic Stem Cell (hESC) Starter Kit ... to get started culturing hESCs as soon as ... in stem cell training courses around the world, ... these products has been extensively tested using GIBCO's ...
    ...
    Request Info...
    Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
    Biology Products: